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ABSTRACT 
 
 The appreciated, yet relatively unexplored, role of the complex tumor 
microenvironment in cancer progression provides a novel avenue to target 
cancer. Oncogenic signaling networks between stromal and cancer cells 
inherently exist, but have yet to be readily identified, and more importantly, 
understood at the molecular level. To systematically identify these signaling 
networks, we utilized the well-characterized vulvagenesis program 
of Caenorhabditis elegans (C. elegans). During vulva development, 
mesenchymal cells signal to adjacent epithelial vulva precursor cells (VPCs) 
through the Ras signaling pathway to promote the cell proliferation and 
patterning that form a mature vulva. This developmental signaling is akin to the 
cellular signaling interactions between stromal mesenchymal cells and epithelial 
cancer cells within a tumor. Consistent with their hallmark role in the formation of 
many human cancers, activating mutations in the RAS (let-60) oncogene in C. 
elegans lead to the hyper proliferation of epithelial VPCs, which presents as a 
multiple-vulva (MUV) phenotype. To elucidate signaling networks derived from 
the mesenchymal cells (which model stroma) that promote hyper proliferation in 
epithelial VPCs (which model cancer cells) in the context of mutant RAS (let-60), 
we conducted a genome-wide “stroma-specific” RNAi screen in C. elegans. The 
screen identified 60 “candidate genes”, 42 with corresponding mammalian 
orthologs, whose activity in the mesenchymal cells contribute to the epithelial 
MUV phenotype. Subsequent studies were initiated to probe the mechanisms 
and pathways through which these “candidate genes” act. The overarching 
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challenge is to translate the identified mammalian orthologs into clinically 
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1.1 The tumor microenvironment as a facilitator of tumor progression: 
 Solid tumors are comprised of cancerous cells as well as a heterogeneous 
environment of fibroblasts, extracellular matrix, endothelial cells, immune cells 
and other stromal components [1]. Tumor stroma and wound-healing stroma are 
both compromised of a myriad of fibroblasts, a striking histological similarity that 
may highlight the important role of fibroblasts in the tumor microenvironment [2]. 
In addition to visual similarity, tumor stromal fibroblasts function in an analogous 
manner. They stimulate ECM growth and release cytokines and growth factors 
through intercellular signaling in an attempt to “heal” the prevailing carcinoma in 
situ [3]. Notably, wound-healing fibroblasts are deactivated following their 
restorative function while tumor-stromal fibroblasts remain activated. 
Consequently, the constant signaling between stromal-fibroblasts and cancer 
cells is believed to result in cancer progression and development [4]. Our lab has 
confirmed the role of PTEN in stromal-fibroblasts in cancer development. PTEN 
was knocked-down in stromal fibroblasts in mouse models in which the 
oncogene ErbB2 (HER2) was overexpressed in the mammary epithelial cells 
through the MMTV promoter. The consequence was an increase in tumor 
incidence, tumor size, and carcinoma progression, highlighting the key role of 
stromal-fibroblasts in reprogramming gene expression in the mammary-gland 
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microenvironment (Figure 1) [5]. This was the first instance that our lab identified 
the in vivo influence of stromal genes on tumor development. 
 
1.2 The KRAS-mutant tumor microenvironment: 
 
 The KRAS signaling pathway, a growth factor propagator, plays a vital role 
in one of the deadliest human cancers, pancreatic adenocarcinoma (5 year 
survival rate: 5.8%), since over 95% of cases involve a mutation in the KRAS 
gene [6][7]. Furthermore, nearly 40,000 American lives will be lost to pancreatic 
adenocarcinoma in 2015, making it the 4th deadliest type of cancer in the U.S. 
[8]. Hyperactive KRAS signaling is also associated with lung and colorectal 
cancers while the HRAS and NRAS signaling pathways, completing the RAS 
family, are also well characterized human cancer provokers. Dense tumor stroma 
proliferation, known as desmoplasia, is a hallmark of pancreatic cancer created 
by the abundance of pancreatic fibroblasts and human pancreatic stellate cells 
(HPSC), cells that function analogously to fibroblasts [9][10][11]. Conditioned 
medium containing HPSCs, isolated from pancreatic adenocarcinoma, triggered 
increased in vitro tumor cell proliferation, migration, invasion, and resistance to 
radiation and gemcitabine in pancreatic cancer cell lines. Injection of HPSCs and 
pancreatic tumor cells in an orthotropic model produced equivalent results: 
increased tumor size and metastasis [9]. Additionally, irradiated stromal-
fibroblasts increase the invasiveness of pancreatic cancer, rendering radiation 
treatment counterproductive [12]. Pancreatic cancer treatment is further 
undermined through tumor-stroma signaling that establishes chemoresistance 
[13]. Since effective treatments for pancreatic adenocarcinoma are nonexistent, 
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novel therapeutic strategies targeting stromal-fibroblast derived cell non-
autonomous signaling networks that interact with the KRAS pathway to facilitate 
pancreatic tumor progression may be a useful therapeutic intervention. 
 
1.3 Modeling the KRAS-mutant tumor microenvironment in C. elegans 
vulva development  
 
 Caenorhabditis elegans (C. elegans) are a very small, about 1mm in 
length, nematode that feed on bacteria, such as Escherichia coli (E. coli), and are 
easily cultivated and housed. Additionally, their well conserved genome, about 
47% homologous with the human genome, paired with their short life and 
reproductive cycle, relative to mice, drastically expedites the experimental cycle, 
making C. elegans amenable to genome-wide/large-scale studies [14]. C. 
elegans vulva development is a tightly regulated process of cell division and 
migration that results in an organized 22-cell vulva. Importantly, this process 
depends on signaling between mesenchymal and epithelial cells while utilizing 
three highly conserved human cancer related pathways: Ras, Wnt, and Notch 
[15]. This signaling between mesenchymal and epithelial cells to promote the cell 
proliferation and patterning that leads to the formation of a mature vulva (the egg 
laying organ) is akin to the signaling interactions between a tumor and its 
microenvironment. In wild type C. elegans vulva development, three of the six 
vulva precursor cells (VPCs) are directed by the aforementioned signaling 
pathways (Ras, Wnt, Notch) to differentiate into mature vulva cells while the 
remaining three cells differentiate into non-specific hypodermal cells [16]. 
 Contrary to the three RAS family genes in humans, the C. elegans 
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genome only houses one RAS gene (let-60). As a result, the C. elegans Ras 
signaling pathway corresponds to and is highly conserved with the KRAS 
signaling pathway as well as the HRAS and NRAS signaling pathways. 
Correspondingly, any findings in C. elegans could be applicable to KRAS, HRAS 
and NRAS related cancers. Specifically, the let-60 gene is a member of the 
developmental Ras pathway, and furthermore, an ortholog of the human RAS 
proto-oncogene [17]. A gain-of-function (gf) let-60 mutation in C. elegans hyper-
activates the Ras signaling pathway, altering normal vulva development by 
influencing more than three VPCs to differentiate into mature vulva cells and 
ultimately resulting in the multiple vulva (MUV) phenotype. Although MUV is a 
much more controlled increase in proliferation than cancer, it still represents an 
undeniable increase in abnormal growth inducing signaling. 
 
1.4 Hypothesis and Specific Aims 
 
 Cancer research has largely ignored the tumor microenvironment and 
focused almost exclusively on the role of cancer cells themselves. This leaves us 
with limited knowledge concerning the mechanisms and role of genetic signaling 
pathways in the entire tumor. Our main hypothesis is that the tumor 
microenvironment plays a crucial role in tumor growth and progression and, more 
specifically, that unidentified stromal genes exacerbate human tumor 
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Specific aim 1: Identify novel stromal-derived oncogenic-like signals that provoke 
excessive RAS-mutant epithelial cell proliferation. 
 
 Mammalian models that study the tumor microenvironment are restricted 
to the analysis of one gene at a time. We overcame this limitation by conducting 
a genome-wide stroma-specific RNAi screen in C. elegans to systematically 
identify novel stromal-derived oncogenic-like signals that enhance Ras mediated 
cell proliferation.  
 
Specific aim 2: Functional analysis of “candidate genes” in the Ras signaling 
pathway. 
 
 To partially address how identified “candidate genes” might be eliciting 
their oncogenic-like effect on epithelial cell growth I chose to use fluorescent 
reporters of the RAS signaling pathway (egl17::CFP) to visualize the activity of 
candidate genes relative to baseline RAS signaling in VPCs. Since the let-60 
mutation shows over-induction of RAS signaling compared to wild-type let-60 
(data not shown), RNAi knockdown of “candidate genes” that function through 
the Ras signaling pathway should diminish overall Ras reporter signaling while 
knockdown of genes that function downstream or in alternate pathways will not 
alter Ras reporter signaling [18]. The working hypothesis of this aim is that while 
some candidates will work through the Ras signaling pathway, others may be 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 C. elegans strains: 
 C. elegans strains utilized in experiments include the 7.10, GS3582, and 
MT2124 strains. 7.10 was the strain utilized in the genome-wide screen and its 
properties include a let-60 (Ras) gain of function mutation, rrf-3 loss of function 
mutation, rde-1 loss of function mutation, and gonadal, muscle, and anchor cell 
tissue-specific promoters of rde-1. The GS3582 strain expresses a fluorescent 
reporter construct (egl-17p::CFP) for the RAS signaling pathway while the 
MT2124 strain harbors a single let-60 (Ras) mutation. All strains were developed 
in the lab of Dr. Helen Chamberlin and maintained in an incubator at 20 °C. 
 
2.2 Tissue-specific RNAi construct in C. elegans 
 Our lab previously constructed and validated a “stroma”-specific RNAi 
model of C. elegans. To achieve a “stroma”-specific RNAi effect, RNAi machinery 
was inactivated via a mutation of the rde-1 gene, which encodes a protein that is 
vital for transforming precursor RNA into functional dsRNA. In the rde-1 mutant 
C. elegans strain, wild-type rde-1 was reintroduced under the control of three 
stromal-specific promoters (anchor cell, somatic gonad, muscle) to achieve 
tissue-specific knock down. First, we demonstrated tissue-specific expression of 
GFP driven by stroma-specific promoters (Figure 2). 
 Functional validation of the stroma-specific RNAi model utilized lin-3/EGF 
and lin-39, which are both necessary in a tissue specific manner for normal vulva 
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development. The lin-3 gene is required in “stromal” cells while lin-39 function is 
required in VPCs for proper vulva formation [19][20]. Specifically, lin-3 codes for 
a ligand (EGF ligand) released by “stromal” cells while lin-39 codes for a receptor 
(EGFR) on epithelial VPCs that binds the aforementioned ligand. As expected, 
when either lin-3 or lin-39 were knocked down via RNAi in wild type rde-1 C. 
elegans, a vulvaless phenotype was observed (Figure 3A). Conversely, when 
either gene was knocked down in rde-1 mutant C. elegans, a normal phenotype 
was observed (Figure 3B), as RNAi is not functional in this strain of C. elegans. 
Importantly, however, lin-3 RNAi in “stroma specific” rde-1 C. elegans yielded a 
vulvaless phenotype (Figure 3C) while lin-39 RNAi in “stroma-specific” rde-1 C. 
elegans produced a normal vulva phenotype (Figure 3D). These converse results 
illustrate the stroma-specific RNAi functionality of our model. 
 
2.3 C. elegans RNAi screen and microscopy 
 To achieve stroma-specific knockdown, we crossed the aforementioned 
strain of “stroma-specific” rde-1 C. elegans with a let-60 mutant strain. To 
increase C. elegans’ sensitivity to RNAi, a loss-of function mutation in the rrf-3 
gene was also introduced, yielding our final 7.10 strain [21]. We systematically 
screened our strain against the Ahringer Laboratory E. coli RNAi library 
(Bioscience LifeSciences) targeting 16,757 C. elegans genes (81% of the C. 
elegans genome) [22]. RNAi was achieved by feeding the 7.10 strain individual 
E. coli clones expressing double stranded RNA (dsRNA) on a gene-by-gene 
basis. A lab technician was responsible for inoculating E. coli RNAi clones from 
384-well library plates into 96-well deep-well plates (VWR) with Luria broth (LB) 
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medium (Invitrogen) containing 50 µg/mL carbenicillin (Sigma-Aldrich) for 16 
hours at 37°C. The cultured E. coli was then seeded onto 12-well plates 
(Corning) with standard nematode growth medium (NGM) agar, but containing 
double the amount of normal peptone, as well as 25 µg/mL carbenicillin and 1mM 
IPTG (Lab Scientific) and incubated at room temperature for 24 hours. 
Approximately 100 synchronized 7.10 embryos were seeded into each well of the 
12-well plates and incubated for 4 days at 20°C with the cultured E. coli. For the 
primary genome-wide RNAi screen approximately 50 adult C. elegans in each 
well were phenotypically scored for MUV and wild type vulva phenotypes using 
an Olympus SZ60 dissection microscope. 90% of C. elegans in the 7.10 strain 
express the MUV phenotype due to hyperactive Ras signaling (let-60 mutation). 
Correspondingly, genes that yielded a significant reduction in the MUV 
phenotype (>40% reduction) of a C. elegans population when knocked down by 
E. coli clones were evaluated twice more in secondary and tertiary screens. 
Ultimately, genes that yielded significant reductions in the MUV phenotype upon 
stromal-specific RNAi in at least two out of three replications were designated as 
primary “candidate genes”. For practical reasons, the primary, secondary, and 
tertiary screens were carried out with 2 other lab members, James Dowdle, 
Ph.D., and Komal Rambani, M.S. I personally screened 4,226 genes in the 
primary screen (25.2% of the genome) and 110 genes in both the secondary and 
tertiary screens. Primary “candidate genes” were individually re-evaluated, also 
using the 12-well plate RNAi platform, but in this instance plates were incubated 
at 20°C for 48 hours and only L4 stage worms were selected for imaging. DIC 
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images were captured with a Spot RT Monochrome digital camera (Diagnostic 
Instruments) using a Zeiss Axioskop2 microscope to confirm the reversion of the 
MUV phenotype to wild type vulva phenotype upon stromal “candidate gene” 
depletion at high magnification (1000x). Komal Rambani conducted a majority of 
these high-magnification experiments, but I contributed to the experiments 
evaluating the “candidate genes” from chromosomes III and IV. 
 
2.4 Generation of male C. elegans 
 GS3582 males were generated by “heat shock treatment”: the incubation 
of 5 hermaphrodite C. elegans at the L4 larval stage for exactly 6 hours at 30°C 
[23]. This treatment yielded a small population of males, which were 
subsequently mated with sibling hermaphrodites to generate a larger population 
of male C. elegans. 
 
2.5 Ras reporter genetic cross 
 GS3582 males were crossed with 7.10 hermaphrodites (Figure 4). The 
fluorescent reporter construct (egl-17p::CFP) in the GS3582 strain exhibits an 
easily identifiable GFP marker in the neural region of C. elegans while the 7.10 
strain expresses different visual markers: MUV phenotype (as a result of the let-
60 mutation), and a global GFP expression pattern (as a result of the tissue-
specific rde-1 promoters). The rrf-3 and rde-1 mutations in the 7.10 strain 
express no visually traceable markers.  
 To initiate the cross, three GS3582 males at the L4 larval stage were 
plated with five 7.10 hermaphrodites at the L4 larval stage and incubated at 20°C. 
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5 days later, 25 F1 progeny displaying the three visual markers (neural GFP, 
multiple vulva phenotype, global GFP) were isolated and allowed to self-
propagate. Six F2 progeny were selected and isolated based on the same visual 
markers and subsequently allowed to self-propagate to confirm true-breeding of 
the markers, and the corresponding homozygous presence of the fluorescent 
reporter, let-60 mutation, and rde-1 tissue-specific promoters. In total, two 
independent crosses were initiated and executed to completion. 
 
2.6 C. elegans DNA extraction: 
 C. elegans populations were expanded until near-starvation, harvested, 
and mixed with 148.2 µL worm-lysis buffer and 1.8 µL proteinase K (5 mg/mL). 
The mixture was stored overnight at -80 °C to enhance cuticle cracking. A PCR 
machine was then utilized to heat the mixture to 65 °C for 1 hour, followed by 
95°C for 15 minutes. The resulting genomic DNA (gDNA) was stored at 4°C and 
used for all subsequent PCR experiments. 
 
2.7 Genotyping - PCR and electrophoresis: 
 Since the rrf-3 and rde-1 mutations display no phenotypic markers, their 
presence was probed through PCR and, in the instance of the rrf-3 mutation, the 
subsequent analysis of DNA amplification products via electrophoresis. rrf-3 was 
amplified by 20 µL PCRs (Table 1) and run out on a 2% agarose gel at 120 V for 
35 minutes and analyzed with a FluorChem E System imager (ProteinSimple). 
rde-1 was amplified via 50 µL PCRs (Table 2). The rde-1 mutation is a point 
mutation, resulting in the inability to detect a difference between the WT and 
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mutant gene amplification via electrophoresis. Accordingly, 10 µL of each rde-1 
amplifying PCR was analyzed by electrophoresis simply to confirm the presence 
of amplified rde-1.  
 
2.8 Genotyping - sequencing: 
 The remaining 40 µL from rde-1 amplifying PCRs was purified with a PCR 
Purification Kit (Qiagen) to obtain pure DNA. The concentration of isolated DNA 
was measured with a spectrophotometer (NanoDrop, Wilmington, Delaware, 
USA) and then submitted for sequencing at The Ohio State University 
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3.1 Stromal factors contribute to Ras-mediated epithelial cell proliferation 
 
 The Ahringer Laboratory E. coli RNAi library containing 16,757 RNAi 
clones, which accounts for approximately 81% of the C. elegans genome, was 
used to systematically feed stroma-rde-1;let-60(-);rrf-3(-) larvae RNAi inducing E. 
coli clones on a gene-by-gene basis [22]. A >40% reduction in MUV phenotypes 
was used as the primary end-point for reduced abnormal Ras-driven VPC 
proliferation. RNAi that resulted in significantly reduced vulva defects, MUV, in at 
least two of three independent replicates were classified as “candidate genes”. 
Ultimately, screening over 16,000 genes with stroma-specific RNAi identified 60 
stromal “candidate genes” that contribute to the hyper proliferation of epithelial 
vulva cells in the context of hyperactive Ras signaling.  
 Amino acid sequence alignment to the mouse and human proteome 
revealed that 42 of the 60 (70%) final “candidate genes” correspond to 39 
mammalian orthologs (Table 3) (his-73, his-59, and his-32 share the ortholog 
HIST2H3D while his-43 and his-3 share the ortholog HIST2H2AB), whereas only 
47% of all genes in the RNAi library have a mammalian ortholog. This increased 
level of conservation might suggest that stroma-tumor signaling networks 
revealed by this screen are conserved between C. elegans and humans. 
Interestingly, many candidate genes can also be grouped into specific processes, 
such as: histones, membrane proteins (transporters and receptors), ribosomal 
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components, metabolism, and cell cycle/DNA regulators. Although more detailed 
computational analysis is required, the striking convergence of stromal hits on a 
few selected processes seems promising. Additionally, high magnification 
(1000x) validation of candidate genes from chromosomes III and IV confirmed 
the vulva phenotypes observed at low magnification (Table 4). 
 
3.2 Failed Ras reporter genetic cross 
 Two attempted crosses failed to generate a C. elegans strain with the 
desired genetic background: let-60(gf) mutation, rrf-3(lf) mutation, rde-1(lf) 
mutation, Ras Reporter construct (egl17::CFP), and gonadal, muscle, and anchor 
cell tissue-specific promoters of rde-1. In cross 1, out of 6 F2 generation strains, 
all selected for visual markers confirming the presence of the let-60 mutation, 
Ras Reporter construct, and tissue-specific rde-1 promoters, strain 6 exhibited an 
rrf-3 and rde-1 mutant genotype (Table 5). Surprisingly, this genotype reverted to 
an rrf-3 mutant and rde-1 heterozygous mutant genotype in the F3 generation, 
and eventually an rrf-3 mutant and rde-1 wild type genotype in in the F4 
generation (Figure 5). rrf-3 PCR/electrophoresis genotyping (Figure 6) and rde-1 
sequencing (Table 6) of the F4 generation of strain 6 represent the endpoint of 
cross 1. In cross 2, the F2 generation of strain 10 displayed an rrf-3 mutant and 
rde-1 heterozygous mutation (Table 7). However, similar to the occurrence in 
strain 6, strain 10 reverted to an rrf-3 mutant and rde-1 wild type genotype in the 
F4 generation (Figure 7).  
 In addition to following strains 1-12 to conclusion, 20 additional strains 
from crosses 1 and 2 were selected and followed. These strains generally carried 
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homozygous copies of 3 desired characteristics, 1 heterozygous characteristic, 
and heterozygous rde-1 (for example: a strain that was homozygous for rrf-3(lf), 
Ras Reporter construct, tissue specific rde-1 promoters, and heterozygous for 
let-60, and rde-1) in the F2 generation. Similarly to strains 6 and 10, these strains 
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CHAPTER 4 
DISCUSSION AND CONCLUSION 
 
 We hypothesized that unidentified stromal genes exacerbate human 
tumors in an oncogenic manner. Furthermore, we hypothesized that “candidate 
genes” identified through our screen would work through the Ras signaling 
pathway, while others could be eliciting their oncogenic-like effect through 
alternative cross-talking signaling pathways. In summary, there were two aims to 
this study: 
• Identify novel stromal-derived oncogenic signals that enhance Ras-
mediated cell proliferation. 
• Evaluate the mechanism by which identified stroma-specific “candidate 
genes” promote excessive epithelial cell proliferation. 
 
4.1 Novel stromal-derived oncogenic signals enhance Ras-mediated cell 
proliferation 
 
 While the Ahringer Laboratory E. coli RNAi library only targets 81% of the 
C. elegans genome, a more complete E. coli RNAi library does not currently exist 
so it was not possible for us to screen the remaining 14% of the C. elegans 
genome. Additionally, while only 47% of the C. elegans genome is conserved 
with the human genome our “candidate genes” showed a much higher level of 
conservation (70%). Regardless, not all identified “candidate genes” can 
progress to human validation experiments. Although these constraints are 
impossible to overcome, our systemic method is the first in vivo screen to identify 
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stromal oncogenic-like signaling networks that could be highly conserved in the 
tumor microenvironment.  
 As outlined previously, the contribution of the tumor microenvironment to 
tumor development and progression is evident, yet the detrimental mechanisms 
remain unclear, especially in regards to pancreatic cancer. Pancreatic cancer 
remains one of the deadliest cancers and evidence suggests that the few existing 
treatments actually contribute to tumor progression. Accordingly, time is of the 
essence when it comes to developing novel treatments for current and future 
pancreatic cancer patients. Exploiting the vulvagenesis program of C. elegans in 
a systematic manner to expose stromal signaling cascades that enhance Ras-
mediated cell proliferation is the first step to elucidating the genetic contributions 
of the pancreatic tumor microenvironment. Additionally, our model proves more 
physiologically relevant than a potential static in vitro model in which the same 
stromal cells would lie adjacent to the same cancer cells through the duration of 
the experiment, as well as more financially feasible and time conscious than a 
genome-wide screen in a higher-level organism such as a mouse. Ultimately, we 
propose that the identified oncogenic-like stromal signaling pathways may 
provide the opportunity to develop exciting therapeutics that target novel stromal 
pathways in combination with traditional tumor cell targeting treatments. 
 
4.2 Inability to establish a stroma-rde-1;let-60(lf);rrf-3(lf);Ras Reporter C. 
elegans strain 
 
 Based on the results of our cross, the derivation of our desired Ras 
Reporter model via a similar crossing strategy seems unlikely. Specifically, the 
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elusiveness of homozygous mutant rde-1 in our cross suggests lethality or a 
possible growth disadvantage in our desired C. elegans strain. 
 
4.3 Future Studies and Conclusions 
 An alternate approach to deriving a viable Ras reporter strain would be to 
mate male 7.10 C. elegans with hermaphrodite GS3582 C. elegans. Yet another 
approach would be to search the literature for the availability of a C. elegans 
strain harboring a reporter for a different Ras-targeted promoter. Perhaps 
crosses utilizing a reporter different from the GS3582 reporter would prove more 
successful. 
 If neither of the aforementioned strategies yield the desired strain then we 
could also construct a genetically simpler Ras reporter model. A C. elegans 
model consisting of just the Ras Reporter construct and a let-60 mutation would 
not be as ideal, but would also display the effect of “candidate gene” knockdown 
on vulval Ras signaling. Such a model has been used in the past in our lab to 
evaluate “candidate genes” in a previous genome-wide screen. 
 In regards to the genome-wide screen, the possibility exists that our 
primary screen might have elicited false negative results. To combat this, we plan 
on grouping identified candidate genes by gene families. If a significant number 
of candidate genes are housed within a specific gene family then we can set up 
additional RNAi experiments for the genes in that family that were not identified 
as “candidate genes” in the initial genome-wide screen. 
 The possibility also exists that our stroma-specific RNAi model is not 
100% stroma-specific. While we intended to only knockdown genes in the 
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mesenchymal cells in our experiments, it’s possible that the RNAi effect “leaked” 
into the epithelial VPCs. A graduate student has developed a VPC-specific 
experimental strain to address this possbility. They are currently knocking down 
“candidate genes” in the VPC-specific strain and documenting the vulva 
phenotypes. If knockdown of the “candidate genes” in the VPC-specific strain 
does not significantly alter the 90% MUV phenotype, then our stroma-specific 
RNAi model is truly stroma-specific. However if the knockdown of “candidate 
genes” in the VPC-specific strain also reduces the MUV phenotype, then the 
possibility exists that our stroma-specific RNAi model is not truly stroma-specific 
and/or that the “candidate genes” are expressed in both the mesenchymal 
(stromal) and epithelial cells and that gene knockdown in either cell type is 
significant. 
 Identified “candidate genes” will be prioritized for further validation based 
on their expression in human pancreatic cancer associated fibroblasts (CAFs), 
which will be determined via RT-PCR. Candidate genes with the highest 
expression in pancreatic CAFs, relative to normal pancreatic fibroblasts, will be 
given priority. Candidate genes will first be validated by 2D, and subsequently by 
more physiologically relevant 3D, co-culture experiments that examine the effect 
of “candidate gene” knockdown in human pancreatic fibroblasts on human 
pancreatic epithelial cells. In order to produce an even more physiologically 
relevant tumor microenvironment model we also intend to conduct orthotopic 
murine model experiments that explore the influence of “candidate gene” 
knockdowns in human pancreatic fibroblasts on human pancreatic epithelial 
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cells. The aforementioned experiments will begin to explore whether stromal 
“candidate genes” identified in C. elegans may contribute to human pancreatic 
tumor development.  
 We plan to utilize fibroblasts as the primary stromal cell in our validation 
experiments because of their mesenchymal cell classification and abundance in 
the pancreatic tumor microenvironment. The mesenchymal characterization of 
fibroblasts is vital since in our developmental vulva model mesenchymal cells 
(anchor cell, gonad, muscle) signal to epithelial VPCs, similar to mesenchymal 
fibroblasts signaling to epithelial cancer cells in the pancreatic tumor 
microenvironment. If feasible, we are also interested in evaluating candidate 
genes in other stromal cell types, such as macrophages.  
 In conclusion, we identified 60 novel stromal factors, 42 with 
corresponding mammalian orthologs, that enhance Ras-mediated epithelial cell 
proliferation in C. elegans vulva development. Once confirmed as agitators of 
tumor growth and development in mouse and human models, these “candidate 
genes” could provide novel stromal specific drug targets and biomarkers for 
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no expression in cytokeratin-positive epithelial cells, F4/80-positive
macrophages and CD31-positive endothelial cells (Fig. 1a and
Supplementary Fig. 2a, b). Western blot and PCR assays demon-
strated efficient cre-mediated deletion of PtenloxP in stromal fibro-
blasts isolated from Fsp-cre;PtenloxP/loxP mammary glands (Fig. 1b
and Supplementary Fig. 3a). Examination of mammary sections by
immunohistochemistry (IHC) and immunofluorescence showed
deletion of PtenloxP that was confined to stromal fibroblasts, with
no collateral deletion in epithelial ducts or the adjacent myoepithe-
lium (Fig. 1c and Supplementary Fig. 3b, c). Interestingly, this
resulted in the expansion of the ECM, but did not lead to the trans-
formation of the mammary epithelium (Fig. 1c, e).
We then examined the role of stromal Pten on mammary tumori-
genesis using an established mouse model of breast cancer, MMTV-
ErbB2/neu (ErbB2)16. To avoid possible confounding effects caused
by Pten deletion in mesenchymal cells of other organs, mammary
glands from Fsp-cre;PtenloxP/loxP, ErbB2;PtenloxP/loxP and ErbB2;Fsp-
cre;PtenloxP/loxP donors were transplanted into syngeneic wild-type
recipients17 and tumour development was monitored over the course
of several months. By genetically marking the stroma with the
Rosa26LoxP reporter allele, we demonstrated that both the epithelium
and its associated stroma were effectively transplanted into host
female mice (Supplementary Fig. 4). Loss of Pten in stromal fibroblasts
dramatically increased the incidence of ErbB2-driven mammary
tumours (Fig. 1d–f). By 16 weeks post-transplantation, these lesions
progressed to adenoma, carcinoma in situ and invasive carcinoma
(Fig. 1g), and by 26 weeks most females met the criteria for early
removal due to excessive tumour burden (Fig. 1f). Histological exami-
nation showed that ErbB2-tumour cells in Pten stromal-deleted
tumours retained their typical oncogene-specific morphology, with
small nuclei, fine chromatin and abundant eosinophilic cytoplasm18.
In contrast to non-deleted tumours18,19, Pten stromal-deleted tumours
had a significant amount of stroma surrounding and infiltrating the
epithelial masses (Fig. 1g). PCR-based and immunohistochemical
assays confirmed that tumours had intact PtenloxP alleles in the epi-
thelial compartment (Supplementary Fig. 5a, b and data not shown).
Moreover, we used the Rosa26loxP reporter allele to mark genetically
early epithelial to mesenchymal transition events15 and found no evid-
ence of epithelial to mesenchymal transition in tumours that either
contained or lacked Pten in stromal fibroblasts (data not shown).
Thus, the analysis of the ErbB2 breast-cancer tumour model identified
a potent tumour suppressor role for Pten in stromal fibroblasts of the
mammary gland.
Stromal Pten controls ECM and innate immune functions
To investigate the tumour suppressive mechanism of Pten action in
stromal fibroblasts, we profiled the transcriptome of mammary stromal
fibroblasts isolated from PtenloxP/loxP and Fsp-cre;PtenloxP/loxP females.
Details of sample collection, processing of Affymetrix oligo-arrays and
expression data are available in Methods. Briefly, we implemented class
comparison analyses of all probe sets on the Affymetrix mouse genome
430 2.0 array to identify genes differentially expressed between the two
genetic groups. We also used an unbiased approach similar to gene set
enrichment analysis20 to identify a priori defined groups of genes that
were significantly differentially expressed. The analysis of over 14,000
mouse genes identified 129 upregulated and 21 downregulated unique
genes in response to Pten deletion (Supplementary Fig. 6a, b; greater
than fourfold at P , 0.001; Supplementary Tables 1 and 2). Reverse
transcription followed by quantitative PCR (quantitative RT–PCR)
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Figure 1 | Stromal fibroblast-specific deletion of Pten. a, Wholemount,
X-gal-stained mammary glands from Fsp-cre;Rosa1/loxP and Rosa1/loxP (top,
inset) mice. Higher magnification of wholemount gland (bottom left) and a
histological cross section (bottom right); scale bar, 30 mm. lu, Lumen; epi,
epithelium; str, stroma. b, Representative western blot analysis of mammary
fibroblast lysates derived from 8-week-old PtenloxP/loxP mice with (1) or
without (2) Fsp-cre. c, Paraffin sections from 8-week-old female mammary
glands stained with a Pten-specific antibody; lower panels represent higher
magnifications of boxed areas; scale bars: top panels, 200mm; bottom panels,
30 mm. lu, Lumen; epi, epithelial compartment; str, stromal compartment;
red dotted line indicates the border between the two compartments.
d, Tumours collected at 26 weeks post-transplantation. e, Tumour
development by 16 weeks in mammary glands with the indicated genotypes.
Tumorigenicity was determined by palpation or histological presentation of
adenoma/carcinoma at each implantation site and statistically analysed
using Fisher’s exact test. n, Total number of transplants. f, Total tumour
burden at 26 weeks post-transplantation in mammary glands with the
indicated genotypes. Values represent mean 6 s.d. Differences were tested
using the non-parametric Wilcoxon rank sum test. g, H&E-stained sections
of mammary glands harvested at time of transplantation (0 weeks) and
indicated times post-transplantation; scale bars, 100 mm.
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Figure 1. Before (left) and after (right) 
ablation of the PTEN gene in stromal 
fibroblasts surrounding an epithelial 
tumor harboring an ErbB2 mutation. 
 
 
Figure 2. Stroma-specific promoters. Images 
courtesy of Huayang Liu. 
Figure 3. Stroma-specific RNAi confirmation.  Please 
note that singular arrows point to mature vulvas while 
multiple arrows point to cells that should have 
become part of a mature vulva and thus represent a 
vulvaless phenotype. Images courtesy of Huayang 
Liu. 
A	  




Figure 4. stroma-rde-1;let-60(lf);rrf-3(lf);Ras Reporter crossing schematic. 
	   	   29	  







6a" 6b" 6c" 6d" 6e" 6f"
rrf-3 mutant / rde-1 mutant 
rrf-3 mutant / rde-1 heterozygous 
rrf-3 mutant / rde-1 wild type 
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Figure 6. rrf-3 genotyping of the strain 6, F4 generation. 
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Figure 7. Evolution of rde-1 genotype in strain 10. 
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Reagent Volume,per,Reaction,(uL) Reaction,Step Temperature,and,Time
DNA 0.5'uL 1 94'°C'for'3:00'minutes
10x'PCR'Buffer 2.0'uL 2 94'°C'for'0:30'minutes
MgCl2 1.6'uL 3 55'°C'for'0:30'minutes
dNTPs 0.2'uL 4 72'°C'for'2:00'minutes
Tag 0.2'uL 5 Go'to'step'1,'40X
rrf#3%FL'Primer 0.5'uL 6 72'°C'for'3:00'minutes
rrf#3%#R 'Primer 0.5'uL 7 4'°C'for'∞
dH2O 14.5'uL
Reagent Volume,per,Reaction,(uL) Reaction,Step Temperature,and,Time
DNA 1%uL Step%1 94%°C%for%3:00%minutes
10x%PCR%Buffer 5%uL Step%2 94%°C%for%0:30%minutes
MgCl2 4%uL Step%3 55%°C%for%0:30%minutes
dNTPs 0.5%uL Step%4 72%°C%for%2:00%minutes
Tag 0.5%uL Step%5 Go%to%step%1,%40X
Primer%#1 1%uL Step%6 72%°C%for%3:00%minutes
Primer%#2 1%uL Step%7 4%°C%for%∞
dH2O 37%uL
Table 1. rrf-3 PCR. 
Table 2. rde-1 PCR. 
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Chr. C.#elegans%Gene%Name Mammalian%Ortholog Gene%Description
II his%73 HIST2H3D histone1cluster12,1H3d
II his%43 HIST2H2AB histone1cluster12,1H2ab
IV his%59 HIST2H3D histone1cluster12,1H3d
IV his%32 HIST2H3D histone1cluster12,1H3d
IV his%46 HIST1H4G histone1cluster11,1H4g
V his%39 HIST2H2BE histone1cluster12,1H2be
V his%8 HIST2H2BF histone1cluster12,H2bf
V his%3 HIST2H2AB histone1cluster12,1H2ab
X his%71 H3F3B H31histone,1family13B1(H3.3B)
I scav%6 SCARB1 scavenger1receptor1class1B,1member11
I F57B10.5 TMED7 transmembrane1emp241protein1transport1domain1containing17
I ncx%4 SLC24A2 solute1carrier1family1241(sodium/potassium/calcium1exchanger),1member12
II fgt%1 SLC2A3 solute1carrier1family121(facilitated1glucose1transporter),1member13
II F46B3.9 VLDLR very1low1density1lipoprotein1receptor
X clec%210 MRC1 mannose1receptor,1C1type11
X gyc%11 NPR1 natriuretic1peptide1receptor11
X gpn%1 GPC4 glypican14
I rpl%24.1 RPL24 ribosomal1protein1L24
I C37A2.7 RPLP2 ribosomal1protein,1large,1P2
II rpl%41 RPL36AL ribosomal1proten1L36a%like
II W01D2.1 RPL37 ribosomal1protein1L37
IV lars%1 IARS isoleucyl%tRNA1synthetase
IV rps%18 RPS18 ribosomal1protein1S18
I F14B4.2 HK2 hexokinase12
IV fat%6 SCD stearoyl%CoA1desaturase1(delta%9%desaturase)
V hpo%18 ATP5E ATP1synthase,1H+1transporting,1mitochondrial1F11complex,1epsilon1subunit
V atp%4 ATP5J ATP1synthase,1H+1transporting,1mitochondrial1F01complex,1subunit1F6
V atp%5 ATP5H ATP1synthase,1H+1transporting,1mitochondrial1F01complex,1subunit1d
V pyc%1 PC pyruvate1carboxylase
I F25H5.5 CLSPN claspin
III W04A8.1 MCPH1 microcephalin11
III F54H12.2 RRM2B ribonucleotide1reductase1M21B1(TP531inducible)
I C27A12.2 ZNF79 zinc1finger1protein179
I phip%1 PHPT1 phosphohistidine1phosphatase11
II C26D10.3 PYROXD1 pyridine1nucleotide%disulphide1oxidoreductase1domain11
II gst%24 HPGDS hematopoietic1prostaglandin1D1synthase
IV mig%28 PRG4 proteoglycan14
IV VHA%3 ATP6V0C ATPase,1H+1transporting,1lysosomal116kDa,1V01subunit1c
IV VHA%11 ATP6V1C1 ATPase,1H+1transporting,1lysosomal142kDa,1V11subunit1C1
V F46B6.5 SRRM5 serine/arginine1repetitive1matrix15
V Y59A8B.19 MUC19 mucin119,1oligomeric







Table 3. “Candidate genes” with mammalian orthologs identified in genome-wide screen. 
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Total C. elegans 
observed
III his-59 HIST2H3D 10 44
III his-32 HIST2H3D 6 41
IV his-46 HIST1H4G 1 26
IV Iars-1 IARS 5 50
IV rps-18 RPS18 8 40
IV fat-6 SCD 9 50
IV W04A8.1 MCPH1 0 30
IV F54H12.2 RRM2B 1 31
IV mig-28 PRG4 16 29
IV VHA-3 ATP6V0C 13 50
IV VHA-11 ATP6V1C1 26 50
Table 4. High-magnification validation of candidate genes from chromosomes III and IV. 








Table 5. Genotypes of cross 1, F2 generation. 
Strain Primer Sequence rde-1 allelic genotype
6a rde-1 F1498 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT >1597Wild type
6a rde-1 R139 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT > 238Wild type
6b rde-1 F1498 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTRAAGTTCATGAGAAGCCACAAAGATACAAGAAT >1597Wild type
6b rde-1 R139 > TCCCCACCTACCACTAGTCAAAGKTAAAAGTGGAGCAAAAGAATACGCTGTRCCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT > 238Wild type
6c rde-1 F1498 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT >1597Wild type
6c rde-1 R139 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT > 238Wild type
6d rde-1 F1498 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT >1597Wild type
6d rde-1 R139 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT > 238Wild type
6e rde-1 F1498 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT >1597Wild type
6e rde-1 R139 > TCCCCACCTACCACTAGTCAAAGKTAAAAGTGGAGCAAAAGAATACGCTGTRCCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT > 238Wild type
6f rde-1 F1498 > TCCCCACCTACCACTAGTCAAAGTTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT >1597Wild type
6f rde-1 R139 > TCCCCACCTACCACTAGTCAAAGKTAAAAGTGGAGCAAAAGAATACGCTGTACCAATGGAACATCTTGAAGTTCATGAGAAGCCACAAAGATACAAGAAT > 238Wild type
Table 6. rde-1 genotyping of the strain 6, F4 generation. 
Table 7. Genotypes of cross 2, F2 generation. 
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